11.25.25 -- Improving Sponsor–CMO Collaboration Around Digital Deviations

This resource provides a clear roadmap for delivering advanced sterile injectable therapies with confidence, meeting both regulatory demands and patient needs without compromise.

To execute complex viral product manufacturing, a service provider needs expertise in adherent cell culture capabilities, cell line productivity, and the intricacies associated with these products.

Learn about the partnership that enables Transcat to meet regulatory requirements while focusing on core R&D and accelerating the delivery of life-changing therapies.

Discover why digitization is crucial for cell and gene contract manufacturers by learning the various benefits digital transformation can offer such as efficiency, compliance, and innovation.

Hear how one family, driven by urgency, partnered with AAV experts to develop a treatment for their daughter’s ultra-rare neurodegenerative disorder, NEDAMSS, in just 14 months.

Explore the development steps that lead to an mRNA construct optimized for your requirements and that meets future-proof cGMP manufacturing requirements, thereby de-risking the development.

The ISABEL trap, which deploys interferometric scattering as a highly sensitive, fluorophore-label-free detection scheme, enables precise interpretation of the actions of complex biomolecular nanoparticles.

Gain expert insights on how tailored approaches and innovative technologies enable fast and flexible development workflows, ultimately supporting rapid therapeutic breakthroughs.

Explore a platform process towards the production of Fab-siRNA conjugates that proves to be scalable and efficient. Find out more about how bioconjugation services can improve your discovery program.

Access a thorough investigation that delves into the critical aspects of expediting curative therapies, with a focus on the strategic role that CDMOs can play in this transformative journey.

Strategically optimize your upstream and downstream processes and decrease the timeline from optimization to commercial manufacturing.

Examine the key findings of a new wearable injector clinical trial, including its positive impact on patient experience and the broader benefits of wearable injectors for chronic disease management.

Discover how Synthego's proprietary synthetic sgRNA, combined with Lonza’s 4D-Nucleofector®, enabled highly efficient gene editing in resting human CD4+ T cells.